ResApp Health Limited (via Public) / ResApp receives $818,826 in R&D tax incentive refund publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Date Time
ResApp: Publication of COPD data and new commercial agreement
Digital health company ResApp Health (ASX:RAP) has announced the publication of acute exacerbation of chronic obstructive pulmonary disease data from its Breathe Easy adult clinical study and a new commercial agreement with Australian-based telehealth company Doctors on Demand.
ResApp Health is developing smartphone applications for the diagnosis and management of respiratory disease. The data from its Breathe Easy adult clinical study has been published in the peer-reviewed Nature Partner Journal, npj Digital Medicine.
The company said the publication – ‘Identification of acute exacerbations of chronic obstructive pulmonary disease using simple patient-reported symptoms and cough feature analysis’ – builds on the preliminary top-line data from the study that was released in April 2019.